To the Editor. — In a recent communication, Allen et al1 report that indomethacin, a compound used for some time2 to reduce diuresis in nephrogenic diabetes insipidus, may also be effective in patients in whom this condition has been induced by lithium therapy. Since in the interpretation of their results, indomethacin is used virtually synonymously with "NSAID" the authors should be reminded that both in healthy subjects and in a patient with nephrogenic diabetes insipidus, the comparison of the potential antidiuretic effect of indomethacin vs that of acetylsalicylic acid, another inhibitor of cyclo-oxygenase activity, has indicated that a mechanism other than cyclo-oxygenase inhibition is involved in the effect of indomethacin.3,4 To relate the antidiuretic action of indomethacin in nephrogenic diabetes insipidus only to its effect on cyclo-oxygenase is therefore an oversimplification.
VIERHAPPER H. Indomethacin in the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus. Arch Intern Med. 1990;150(11):2420. doi:10.1001/archinte.1990.00390220146042
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: